Test axitinib plus immunotherapy before kidney cancer surgery
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether taking axitinib plus an immunotherapy drug (PD-1) before surgery can help people with kidney cancer live longer without the cancer coming back. It’s focused on people who have a higher-risk kidney tumor based on scans and pathology findings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 80 years old and can sign the consent form
- Your kidney cancer is clear cell kidney cancer (or mostly clear cell) on biopsy
- Your scan/staging shows tumor stage T2 with certain features, or T3–T4 with lymph node involvement (N1)
- You feel mostly able to carry on daily activities (ECOG 0 or 1)
- Your heart, liver, and kidney tests are strong enough (including kidney filtration, GFR at least 45)
- The cancer has not spread to distant organs (no distant metastasis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether pembrolizumab plus axitinib can shrink kidney cancer before surgery, when there is tumor growth into the inferior vena cava (IVC). It may help make the operation easier and improve chances of long-term control.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial tests whether adding a cholesterol-lowering drug (atorvastatin) to the standard combination of two cancer drugs (axitinib and toripalimab) can improve outcomes for people with advanced clear cell kidney cancer that cannot be removed by surgery or has spread. The goal is to see if this three-drug approach is safe and effective.
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
This trial tests a combination of targeted therapy (axitinib) and immunotherapy (toripalimab) alongside stereotactic body radiation therapy (SBRT) for kidney cancer that has come back or spread. It may be an option if you have a limited number of metastatic tumors that can be treated with radiation.
This trial tests whether giving immunotherapy before surgery can help people with advanced kidney cancer. The goal is to see if waiting on surgery and starting with medication that boosts the immune system is safe and effective.
Hear when a new Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.